Last week, CSL announced its earnings for the previous fiscal year, virtually of course. It was a chance to bring together employees across the globe to both reflect and shift to what’s next.
Senior Vice President, R&D Strategic Operations, Deirdre BeVard
BeVard gave an overview of R&D work and noted the collaboration shown during CSL’s response to COVID-19. The company is working on multiple projects related to treating and preventing the novel coronavirus.
Noemi Lattanzio, Regulatory Scientist and leader of CSL Behring’s STEM program
Despite COVID-19, Lattanzio said CSL Behring employees at the King of Prussia, Pennsylvania, campus continued to support area students through the Young Men and Women in Charge foundation. Virtual events have included mock interviews and virtual job shadowing and this outreach will continue in 2021, she said.
CSL Limited CEO Paul Perreault
Perreault gave a positive report on the most recent fiscal year. Despite COVID-19 challenges, the future looks bright, he said. CSL, with accomplished businesses in plasma-derived medicines and influenza vaccines, has specific expertise to address the current public health crisis.